Go Pro
NYSEAMERICAN:CLDI

Calidi Biotherapeutics Q1 2026 Earnings Report

Calidi Biotherapeutics logo
$1.08 0.00 (0.00%)
Closing price 04:10 PM Eastern
Extended Trading
$1.08 +0.00 (+0.46%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Calidi Biotherapeutics EPS Results

Actual EPS
-$6.88
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Calidi Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Calidi Biotherapeutics Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Calidi Biotherapeutics Earnings Headlines

A new kind of civil war is coming after election day?
Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the political and investment landscape. Whitney Tilson believes tensions may come to a head at midnight on November 4th, the day after the midterm elections, with major implications for your portfolio.tc pixel
See More Calidi Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Calidi Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calidi Biotherapeutics and other key companies, straight to your email.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) is a clinical-stage biotechnology company developing stem cell-based therapies designed to improve the delivery and effectiveness of cancer treatments. The company’s approach uses allogeneic stem cells as protective carriers that can transport therapeutic agents into tumors while helping shield those agents from the body’s immune system.

Calidi’s technology platforms include NeuroNova, which is based on neural stem cells, and SuperNova, which uses engineered allogeneic stem cells. Its development programs have focused on potential treatments for solid tumors, including recurrent glioblastoma, and are intended to support the delivery of oncolytic viruses and other anti-cancer payloads directly to tumor sites.

Founded in 2014 and headquartered in San Diego, California, Calidi Biotherapeutics became a publicly traded company through a business combination in 2023 and trades on the NYSE American under the symbol CLDI. The company’s programs remain in clinical development, and its research and potential commercial activities are focused on oncology applications.

View Calidi Biotherapeutics Profile